Strongbrigde Biopharma 200 Prozent Potential?
Seite 1 von 2 Neuester Beitrag: 16.02.22 17:20 | ||||
Eröffnet am: | 11.11.15 20:58 | von: Balu4u | Anzahl Beiträge: | 45 |
Neuester Beitrag: | 16.02.22 17:20 | von: Balu4u | Leser gesamt: | 12.832 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < | 2 > |
http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835
Pipeline
http://www.strongbridgebio.com/pipeline/
http://www.finanznachrichten.de/...ien/strongbridge-biopharma-plc.htm
~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~
~ MACRILEN is Strongbridges Second Commercial Product; Expands the Companys Rare Endocrine Disease Portfolio and Complements its Late-Stage Clinical Development Program for RECORLEV (levoketoconazole) in Endogenous Cushings Syndrome ~
~ Strongbridge Expands Structured Financing Facility with CRG to Support the Anticipated Commercial Launch of MACRILEN in Mid-2018 ~
GlobeNewswire•February 23, 2018
https://finance.yahoo.com/news/...plc-announces-annual-123000559.html
Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.